Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease

Gutiérrez Aguirre, César Homero y Cantú Rodríguez, Olga Graciela y Borjas Almaguer, Omar David y González Llano, Óscar y Jaime Pérez, José Carlos y Solano Genesta, M. y Gómez Guijosa, Miguel Ángel y Mancías Guerra, Consuelo y Tarin, L. y Gómez Almaguer, David (2012) Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica, 97 (5). pp. 717-722. ISSN 0390-6078

[img]
Vista previa
Texto
627.pdf - Versión Publicada
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (289kB) | Vista previa

Resumen

Background Chronic graft-versus-host disease is a common late complication of allogeneic hematopoietic stem cell transplantation. Corticosteroids are the standard initial treatment. Second-line treatment has not been well defined. We evaluated the effectiveness and safety of low doses of alemtuzumab plus low doses of rituximab in the treatment of steroid-refractory chronic graftversus-host disease. Design and Methods Ten men and 5 women were prospectively included in the study. All patients received one cycle of subcutaneous alemtuzumab 10 mg/day/3 days and intravenous rituximab 100 mg on Days +4, +11, +18 and +25. The therapeutic response was measured on Days +30, +90 and +365 of the protocol. Results Median age was 41 years. The main site involved was the oral mucosa (86.7%) followed by the eyes (66.7%), liver (60%), skin (53%), lungs (13.3%) and intestinal tract (6.7%). The overall response was 100% at Day +30 evaluation: 10 patients (67%) had partial remission, 5 (33%) had complete remission. At Day +90 evaluation, 7 (50%) patients had partial remission, 4 (28%) had complete remission; 3 (21%) had relapsed chronic graft-versus-host disease and one patient did not reach the evaluation time point. So far, 5 patients have reached the Day +365 follow-up evaluation; 2 (40%) had partial remission, 2 had complete remission and one experienced chronic graft-versus-host disease progression. Adverse effects were mainly infections in 67% of patients; these were all quickly solved, except for one patient who died from pneumonia. Conclusions This combination therapy appears to be an efficacious and safe treatment for steroid-refractory chronic graft-versus-host disease. Longer follow up to determine the durability of response and survival is required (ClinicalTrials.gov: NCT01042509).

Tipo de elemento: Article
Palabras claves no controlados: alemtuzumab, rituximab, graft-versus-host disease, hematopoietic stem cell transplant.
Usuario depositante: Lic. Josimar Pulido
Creadores:
CreadorEmailORCID
Gutiérrez Aguirre, César HomeroNO ESPECIFICADONO ESPECIFICADO
Cantú Rodríguez, Olga GracielaNO ESPECIFICADONO ESPECIFICADO
Borjas Almaguer, Omar DavidNO ESPECIFICADONO ESPECIFICADO
González Llano, ÓscarNO ESPECIFICADONO ESPECIFICADO
Jaime Pérez, José CarlosNO ESPECIFICADONO ESPECIFICADO
Solano Genesta, M.NO ESPECIFICADONO ESPECIFICADO
Gómez Guijosa, Miguel Ángelmagg770214@yahoo.com.mxNO ESPECIFICADO
Mancías Guerra, ConsueloNO ESPECIFICADONO ESPECIFICADO
Tarin, L.NO ESPECIFICADONO ESPECIFICADO
Gómez Almaguer, DavidNO ESPECIFICADONO ESPECIFICADO
Fecha del depósito: 24 Mayo 2019 14:59
Última modificación: 27 Ene 2020 22:01
URI: http://eprints.uanl.mx/id/eprint/15027

Actions (login required)

Ver elemento Ver elemento

Downloads

Downloads per month over past year